Antituberculosis drugs and new drug development

Current Opinion in Pulmonary Medicine

Volumn 7, Issue 3, 2001, Pages 142-147

  Agrawal, Shrutidevi ^a   Thomas, Narisetty Sunil ^a   Dhanikula, Anand Babu ^a   Kaul, Chaman Lal ^a   Panchagnula, Ramesh ^a,b  

^a Natl Inst Pharmaceut Educ/Res   (India)

^b Natl Inst Pharmaceut Educ/Res   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME INHIBITOR; ETHAMBUTOL; ISOCITRATE LYASE; ISOCITRATE LYASE INHIBITOR; ISONIAZID; NITROIMIDAZOLE DERIVATIVE; NITROIMIDAZOPYRAN; OXAZOLIDINONE DERIVATIVE; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; THIOLACTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANTIBIOTIC THERAPY; CHEMOTHERAPY; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; PATIENT COMPLIANCE; POPULATION RESEARCH; QUALITY OF LIFE; REVIEW; TUBERCULOSIS;

EID: 0035015670     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-200105000-00005     Document Type: Review

References (31)

1. 1 Sinder Jr DE, Kochi A: Global epidemiology of tuberculosis: morbidity and mortality of a worldwide epidemic. J Am Med Assoc 1995, 273:220-226.
2. 2 The economic impacts of tuberculosis: the stop TB initiative 2000 series. WHO/CDS/STB/2000.5. Geneva: World Health Organization; 2000.
3. 3 Baris E: Tuberculosis in times of health sector reform. Int J Tuberc Lung Dis 2000, 4:595-596.
4. 4 Fox W, Ellard GA, Mitchison DA: Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999, 3:S231-S279. This is a comprehensive and complete coverage of the chronological developments in the chemotherapy of tuberculosis for four decades, starting from 1946. It also highlights the outstanding contributions made by the British Medical Research Council in the development of various treatment regimens for the management and treatment of tuberculosis.
5. 5 Treatment of tuberculosis: Guidelines for national programs. WHO/TB/97,220, Geneva: World Health Organization; 1997:25-31.
6. 6 What is DOTS? A guide to understanding the WHO-recommended tuberculosis control strategy known as DOTS. WHO/CDS/CPC/TB/99.270. Geneva: World Health Organization; 1999.
7. 7 Chaisson RE: New developments in the treatment of latent tuberculosis, Int J Tuberc Lung Dis 2000, 4:S176-S181.
8. 8 WHO Guidelines for the management of drug-resistant tuberculosis. WHO/TB/96.210, Geneva: World Health Organization; 1998.
9. 9 WHO Guidelines for establishing DOTS-plus pilot projects for the management of multidrug-resistant tuberculosis (MDR-TB). WHO/CDS/TB/2000.279. Geneva: World Health Organization; 2000.
10. 10 Blomberg B, Spinaci S, Fourie B, et al.: The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis, Bull WHO 2001, 79:61-68.
11. 11 Ellard GA, Fourie PB: Rifampicin bioavailability; a review of its pharmacology and the chemotherapeutic necessity for ensuring optimal absorption, Int J Tuberc Lung Dis 1999, 3: S231-S279. This review mainly discusses the pharmacologic properties of rifampicin, with an emphasis on the need to establish the quality of rifampicin in marketed FDCs. It also highlights the number of volunteers, precision of analytic technique, and appropriate statistical test for the evaluation of rifampicin bioavailability from FDCs.
12. 12 Fourie B, Pillai G, Mcllleron H, et al.: Establishing the bioequivalence of RIF in fixed dose formulations containing INH with or without PYZ and/or ETB compared with single drug reference preparations administered in loose combination (model protocol), WHO/CDS/TB/99.274. Geneva: World Health Organization; 1999.
13. 13 Ruiz-Serrano MJ, Alcalá L, Martinez L, et al.: In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000, 44:2567-2568.
14. 14 Berning SE: The role of fluoroquinolones in tuberculosis today. Drugs 2001, 61:9-18.
15. 15 Takahata M, Mitsuyama J, Yamashiro Y, et al.: In vitro and in vivo antimicrobial activities of T-381 1ME, a novel Des-F(6)-quinolone. Antimicrob Agents Chemother 1999, 43:1077-1084.
16. 16 Zhao BY, Pine R, Domagala J, et al.: Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-B methoxyl group on survival in liquid media and in human macrophage. Antimicrob Agents Chemother 1999, 43:661-667.
17. 17 Woodcock JM, Andrews JM, Boswell FJ, et al.: In vitro activity of BAY-12-8039, a new fluoroquinolone, Antimicrob Agents Chemother 1997, 41:101-106.
18. 18 Ji B, Lounis N, Maslo C, et al.: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1998, 42:2066-2069.
19. 19 Barman Balfour JA, Lamb HM: Moxifloxacin: A review of its clinical potential in the management of community-acquired respiratory tract infections. Drugs 2000, 59:115-139.
20. 20 Diekema DJ, Jones RN: Oxazolidinones: a review. Drugs 2000, 59:7-16.
21. 21 Barbachyn MR, Hutchinson DK, Brickner SJ, et al.: Identification of a novel oxazolidinone (U-100480) with potent antimycobacterial activity. J Med Chem 1996, 39:680-685.
22. 22 Cynamon MH, Klemens SP, Sharpe CA, et al.: Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine model. Antimicrob Agents Chemother 1999, 43:1189-1191.
23. 23 Ashtekar DR, Costa-Perira R, Nagrajan K, et al.: In vitro and in vivo activities of nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 1993, 37:183-186.
24. 24 Slayden RA, Lee RE, Armour JW, et al.: Antimycobacterial action of thiolactomycin: an inhibitor of fatty acid and mycolic acid synthesis. Antimicrob Agents Chemother 1996, 40:2813-2819.
25. 25 Kremer L, Douglas JD, Baulard AR, et al.: Thiolactomycin and related analogues as novel antimycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J Biol Chem 2000, 275:16857-16864.
26. 26 Stover CK, Warrener P, van Devanter DR, et al.: A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 2000, 405:962-966. This paper reports a series of compounds belonging to the nitroimidazopyran nucleus having antituberculosis activity. Unlike the currently available drugs, these compounds were found to be bactericidal against the replicating and static M. tuberculosis with a novel mechanism of action that shares some similarity and contrasts with isoniazid.
27. 27 McKinney JD, Bentrup KH, Munõz-Elias EJ, et al.: Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000, 406:735-738. The paper demonstrates for the first time that the persistence of M. tuberculosis in latent phase is facilitated by isocitrate lyase, an enzyme that is essential for metabolism of fatty acids. Furthermore, this paper emphasizes that the metabolism of M. tuberculosis in vitro is profoundly influenced by host response to infection. This finding opens up a new opportunity for treatment of latent cases.
28. 28 Panchagnula R, Thomas NS: Biopharmaceutics and pharmacokinetics in drug research, Int J Pharm 2000, 201:131-150. This review explains various biopharmaceutical hurdles in new drug development and approaches to overcoming them. The importance of solubility, permeability, and pharmacokinetic properties in new drug development is illustrated with suitable examples. Hence, this review gives a preamble to the current article.
29. 29 Prentis RA, Lis Y, Walker SR: Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985), Br J Clin Pharmacol 1988, 25:387-396.
30. 30 Devane J: Oral drug delivery technology: addressing the solubility/permeability paradigm. Pharm Tech 1998, 68-80.
31. 31 Llpinsky CA, Lombardo F, Dominy BW, et al.: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997, 23:3-25.